Peter Olagunju

Peter serves as senior vice president of technical operations at FerGene where he oversees manufacturing, process and analytical development, quality and supply chain for the company.

Prior to joining the company Peter served as the vice president of patient operations with bluebird bio, a biotech company in Cambridge. In this role, Peter had responsibility for the personalized manufacturing & Centers of Excellence (COE) engagement activities including the collection of patient cells, manufacture of drug product, and operational execution of patient treatments.

During his tenure at bluebird bio, Peter also served as the program leader for Zynteglo®, which was approved by the European Medicines Agency (EMA) for patients with transfusion dependent thalassemia. As program lead, he was responsible for the program development team, which was comprised of cross functional representatives spanning research, development, and commercial.

Prior to bluebird bio, Peter served as senior director, global technical operations at Dendreon where he managed the US and EU manufacturing operations and supply chain, including contract manufacturers, external testing sites, and the apheresis network for those regions.

Earlier in his career, Peter had leadership positions within the quality function at ZymoGenetics, a monoclonal antibody organization that was acquired by BMS in 2011.